Key Highlights
- 128.92% is the three-month raw gain for Atlassian (NASDAQ:TEAM) in the relative strength table, against 128.74% in its single article. Fiscal fourth quarter revenue of USD 1.766 billion rose 28%, per the company results released August 6, 2026, and the shares fell 5.05% to USD 206.16.
- 129.70% is the three-month raw gain for OmniAb (NASDAQ:OABI), against 127.48% in its single article. Second quarter revenue was USD 13.4 million, mainly milestones, and the shares fell 2.85% to USD 4.59 on October 16, 2026 for a USD 668 million market capitalisation.
- 109.36% is the three-month raw gain for Everforth (NYSE:EFOR), a base effect from a USD 18.81 starting price (own arithmetic), while second quarter revenue fell 1.3% to USD 1,007.0 million. The third quarter report is scheduled for October 28, 2026 after the close.
- 113.33% is the three-month raw gain for Cango (NYSE:CANG), against 112.78% in its single article. The second quarter net loss was USD 81.6 million per the 6-K, and the shares trade at USD 3.83 on a USD 157 million market capitalisation.
Atlassian (NASDAQ:TEAM)
The market is paying 7.9 times sales for a company that has guided growth to halve. Atlassian (NASDAQ:TEAM) reported fiscal fourth quarter revenue up 28%, cloud revenue of USD 1.213 billion up 31%, operating income of USD 211 million and free cash flow of USD 475 million, with remaining performance obligations of USD 4.817 billion, up 44%. Fiscal 2027 growth is guided to 13% from 26%, because Data Center revenue is guided down 17% as customers migrate to cloud, which is guided to grow 25.5%. The stock traded at USD 132.15 on January 27, 2026 and is USD 206.16 now. The average analyst target of USD 196.74 sits 9.4% below the October 15 close, and the trailing price to earnings ratio is 204.66. What separates it: the strongest operating results of the four. So what: the rally has fundamental support, but valuation leaves limited room for the guided deceleration. Chief executive Mike Cannon-Brookes plans to buy up to USD 250 million of Class A stock under a Rule 10b5-1 plan, and the fiscal first quarter report date was not confirmed.
OmniAb (NASDAQ:OABI)
Revenue quality is the question, because the quarter that drove the rally was weighted to milestone payments. OmniAb (NASDAQ:OABI) reported USD 13.4 million of second quarter revenue against USD 3.9 million a year earlier, and a net loss of USD 5.9 million against USD 15.9 million. Guidance of USD 32 million to USD 36 million with USD 27.8 million booked in the first half implies USD 4.2 million to USD 8.2 million in the second half (own arithmetic). Cash was USD 52.0 million at June 30, 2026, with a year-end outlook of USD 37 million to USD 41 million. The market capitalisation equals 19.6 times the guidance midpoint (own arithmetic). Partners run 425 programs, 34 of them in clinical development or commercialisation, at a 3.4% average royalty rate. What separates it: revenue depends on partner milestones. So what: results on October 30, 2026 will test milestone timing and the cash path. HC Wainwright reiterated Buy with a USD 11.00 target on August 17, 2026, while consensus is Hold, and any equity raise would dilute holders; none was identified.
Everforth (NYSE:EFOR)
The move reprices a worse case; it does not report growth. Everforth (NYSE:EFOR) beat lowered expectations on July 29, 2026 with adjusted EPS of USD 0.91 against USD 0.82, while revenue fell 1.3%, net income fell to USD 14.2 million from USD 29.3 million and adjusted EBITDA margin was 9.6% against 10.6%. The three-month figure starts from a trough after a 51.69% single-session fall on April 22, 2026, and the price remains 28.3% below the 52-week high of USD 54.94. Net debt was USD 1,285.2 million (own arithmetic), and enterprise value is USD 2.90 billion on a USD 1.61 billion market capitalisation. BMO Capital and Truist set targets of USD 41 and USD 45 on October 9, 2026, above a USD 32.67 consensus. What separates it: the weakest growth and the clearest base effect. So what: guided third quarter adjusted EPS at the USD 1.01 midpoint is 22.9% below the prior year (own arithmetic). A USD 600 million revolver completed in July 2026 extends maturities, and the remaining USD 923 million repurchase authorisation equals 57.3% of market capitalisation, although second quarter buying was USD 11.5 million.
Cango (NYSE:CANG)
The market has doubled the price of a Bitcoin miner whose mining was cash-negative. Cango (NYSE:CANG) mined 656 BTC in the second quarter at a cash cost of USD 73,313 per coin against USD 72,256 of mining revenue per coin (own arithmetic), a loss of USD 1,057 per coin before depreciation. The USD 81.6 million net loss came mainly from non-cash impairment on mining machines, and total assets fell 74.0% to USD 294.4 million since December 31, 2025 (own arithmetic). Cash was USD 10.1 million against USD 49.2 million of debt (own arithmetic), and the company holds 1,056 BTC. Management is converting a Georgia site to GPU computing with up to 3 MW of capacity. What separates it: a strategy pivot, not a recovery in results. So what: no company-specific catalyst was identified for the rise since September 1, and AI compute revenue is expected in the third quarter.
Where Things Stand
Atlassian (NASDAQ:TEAM) has the strongest fundamental support of the four, with 28% revenue growth, USD 475 million of free cash flow and 44% growth in contracted revenue. OmniAb has support through milestones, Everforth through margin repair and refinancing, and Cango the least. Three-month relative strength after a 3.98% implied benchmark gain is 125.72 for OABI, 124.94 for TEAM, 109.35 for CANG and 105.38 for EFOR (own arithmetic), so price strength and fundamentals do not rank alike. Valuation is high for TEAM and OABI, and net debt weighs on EFOR. The next dated catalysts are OmniAb results on October 30, 2026 and Everforth results on October 28, 2026.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...